推荐产品
等級
pharmaceutical primary standard
API 家族
triamterene
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
InChI
1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
InChI 密鑰
FNYLWPVRPXGIIP-UHFFFAOYSA-N
基因資訊
human ... SCNN1A(6337) , SCNN1B(6338) , SCNN1G(6340)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Triamterene USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Triamterene and Hydrochlorothiazide Capsules
- Triamterene and Hydrochlorothiazide Tablets
- Triamterene Capsules
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險分類
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
[Pharmacology of potassium-sparing diuretics: amiloride and triamterene].
G Rorive et al.
Coeur et medecine interne, 17(2), 207-215 (1978-04-01)
R A Carey et al.
Clinical therapeutics, 6(3), 302-309 (1984-01-01)
A small number of patients taking products containing triamterene (TAT) develop renal calculi that contain TAT and its metabolites. Most TAT-containing calculi are composed of various crystalline materials, but a small number consist only of TAT, its metabolites, and a
D A Sica et al.
Nephron, 51(4), 454-461 (1989-01-01)
Triamterene (TA) is a mild 'potassium-sparing' diuretic usually employed in combination with other more potent diuretics in the treatment of hypertension. TA pharmacokinetics and pharmacodynamics in normal volunteers, elderly subjects and in patients with renal and hepatic dysfunction are reviewed.
C Lucas et al.
Journal d'urologie, 88(1), 37-42 (1982-01-01)
Various studies have demonstrated a relationship between nephrolithiasis and the ingestion of certain drugs. We are particularly interested in the effects of triamterene. Five published case studies on patients of both sexes between 43 and 60 years of age have
A Haris et al.
Orvosi hetilap, 137(35), 1907-1914 (1996-09-01)
The group of drugs, so-called "potassium sparing diuretics" represent an important part of our modern therapeutic arsenal. Their "weak diuretic" properties are especially beneficial in cirrhotic patients with ascites, when highly effective loop diuretics may be hazardous. Potassium sparing diuretics
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门